Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female, at least 18 years old.~* Diagnosis of rheumatoid arthritis (RA) for greater than or equal to 3 months.~* Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for greater than or equal to 3 months and on a stable dose for greater than or equal to 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.~* Meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.~* Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled (up to 20% of study population) if they have documented evidence of intolerance to bDMARDs or limited exposure (less than 3 months) and have satisfied required washout periods.~Exclusion Criteria:~* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).~* History of inflammatory joint disease other than RA. History of secondary Sjogren's Syndrome is permitted.~* Subjects who are considered inadequate responders to bDMARD therapy as determined by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks.
- Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.
- Placebo / Upadacitinib 15 mg (Type: EXPERIMENTAL): Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks.
- Placebo / Upadacitinib 30 mg (Type: EXPERIMENTAL): Period 1: Participants receive placebo once daily for 12 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).